PrimeRFP SCOUT · Federal Contract Recompete Brief

75N91019D00021EO 14398 preclinical efficacy and intermediate — University of Texas M D Anderson Cancer Center

University of Texas M D Anderson Cancer Center holds $28.1M across 39 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 3 related awards in the incumbent pipeline. Set-aside status: Unrestricted.

Nih Nci
Awarding office
University of Texas M D Anderson Cancer Center
Recipient
—
Estimated value
AN12
PSC
Unrestricted
Set-aside

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Unrestricted
Contract number75N91019D00021
AgencyNih Nci
Awarding officeNih Nci
Awarding agencyDepartment of Health and Human Services (HHS)
Funding agencyDepartment of Health and Human Services (HHS)
IncumbentUniversity of Texas M D Anderson Cancer Center
UEIS3GMKS8ELA16
PSCAN12
Related solicitationN01CN7701918

EO 14398 PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS is a federal Unrestricted award for Nih Nci held by University of Texas M D Anderson Cancer Center. Estimated value —. Related solicitation N01CN7701918.

EO 14398 PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS

Bonuses end Sept 30

Want the durability read on 75N91019D00021? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

University of Texas M D Anderson Cancer Center — $28.1M obligated across 39 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($28.1M) · all agencies
Department of Health and Human Services (HHS)$27.0M · 96%Department of Veterans Affairs (VA)$1.1M · 4%

Related awards

Same incumbent
75N91019F00131
REPURPOSING OF MACROLIDE ANTIBIOTIC CLARITHROMYCIN FOR THE PREVENTION OF LUNG AND BREAST C…
$8.7M
Apr 14, 2027
36C24524P0903
MED PHYSICS PEER REVIEW SERVICES
$1.1M
Sep 30, 2027
75N97021C00001
OPERATION AND MAINTENANCE OF THE CHIMPANZEE CARE CENTER (CCC)
$8.7M
Aug 31, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Explore more pipelines →

Frequently asked questions

What is contract 75N91019D00021?

75N91019D00021 (EO 14398 preclinical efficacy and intermediate) is a Nih Nci award with an estimated value of —, currently held by University of Texas M D Anderson Cancer Center. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N91019D00021?

Nih Nci awarded 75N91019D00021 to University of Texas M D Anderson Cancer Center.

Who is the incumbent on 75N91019D00021?

University of Texas M D Anderson Cancer Center is the incumbent with $28.1M across 39 related awards in SCOUT’s public footprint.

When does University of Texas M D Anderson Cancer Center’s 75N91019D00021 come up for recompete?

SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75N91019D00021? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75N91019D00021